Targeted functional imaging of estrogen receptors with 99mTc- GAP-EDL

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 3, 2007, Pages 354-362

  Takahashi, Nobukazu ^a   Yang, David J ^a   Kohanim, Saady ^a   Oh, Chang Sok ^a   Yu, Dong Fang ^a   Azhdarinia, Ali ^a   Kurihara, Hiroaki ^a   Zhang, Xiaochun ^a   Chang, Joe Y ^a   Kim, E Edmund ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

99mTc GAP EDL; Biodistribution; Endometriosis; ERK1 2; Tumor imaging

Indexed keywords

DIETHYLSTILBESTROL; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PENTETATE TECHNETIUM TC 99M; POLYGLUTAMATE PEPTIDE 3 AMINOETHYLESTRADIOL CONJUGATE PERTECHNETIC ACID TC 99M; POLYGLUTAMATE PEPTIDE TC 99M; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISSECTION; DRUG DISTRIBUTION; DRUG MUSCLE LEVEL; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOMETRIOSIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL MODEL; EXPERIMENTAL RABBIT; FEASIBILITY STUDY; FEMALE; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; HYSTEROGRAPHY; MOLECULAR IMAGING; NONHUMAN; PERITONEUM; RAT; SCINTIMAMMOGRAPHY; UTERUS; WESTERN BLOTTING;

ANIMALS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; ESTRONE; FEMALE; HUMANS; IMAGE ENHANCEMENT; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; POLYGLUTAMIC ACID; POSITRON-EMISSION TOMOGRAPHY; RABBITS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; RECEPTORS, ESTROGEN; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33847138138     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0191-6     Document Type: Article

References (33)

1. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
2. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985;1:16-9.
3. Bertelsen CA, Giuliano AE, Kern DH, Mann BD, Roe DJ, Morton DL. Breast cancers: estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response. J Surg Res 1984;37:257-63.
4. van Netten JP, Armstrong JB, Carlyle SS, Goodchild NL, Thornton IG, Brigden ML, et al. Estrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers. Eur J Cancer Clin Oncol 1988;24:1885-9.
5. 18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biotherapy Radiopharm 1996;11:235-45.
6. Yang DJ, Li C, Kuang L-R, Tansey W, Cherif A, Price J, et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 1994;55:53-67.
7. 18F]fluorotamoxifen in patients with breast cancer. Clin Imaging 1997;21:332-6.
8. 18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001;42(4):679-84.
9. Aliaga A, Rousseau JA, Ouellette R, Cadorette J, van Lier JE, Lecomte R, et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 2004;31:761-70.
10. Hudelist G, Keckstein J, Czerwenka K, Lass H, Walter I, Auer M, et al. Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis. Fertil Steril 2005;84 Suppl 2:1249-56.
11. Tanahatoe SJ, Lambalk CB, Hompes PG. The role of laparoscopy in intrauterine insemination: a prospective randomized reallocation study. Hum Reprod 2005;20:3225-30.
12. Chenu C, Serre CM, Raynal C, Burt-Pichat B, Delmas PD. Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 1998;22:295-9.
13. Raynal C, Delmas PD, Chenu C. Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 1996;137:2347-54.
14. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006;66:1824-32.
15. 111In-DTPA-tamoxifen analogue. J Pharm Sci 1996;85:553-9.
16. Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, et al. 17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]/NFkappaB cascade. Aging Cell 2005;4:113-8.
17. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-300.
18. Watson CS, Norfleet AM, Pappas TC, Gametchu B. Rapid actions of estrogens in GH3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor-alpha. Steroids 1999;64:5-13.
19. Bi R, Broutman G, Foy MR, Thompson RF, Baudry M. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci U S A 2000;97:3602-7.
20. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002;16:116-27.
21. Dunselman GA, Willebrand D, Land JA, Bouckaert PX, Evers JL. A rabbit model of endometriosis. Gynecol Obstet Invest 1989;27:29-33.
22. Classe JM, Fiche M, Rousseau C, Sagan C, Dravet F, Pioud R, et al. Prospective comparison of 3 gamma-probes for sentinel lymph node detection in 200 breast cancer patients. J Nucl Med 2005;46:395-9.
23. Krynyckyi BR, Chun H, Kim HH, Eskandar Y, Kim CK, Machac J. Factors affecting visualization rates of internal mammary sentinel nodes during lymphoscintigraphy. J Nucl Med 2003;44:1387-93.
24. Fleming JS, Wilkinson J, Oliver RM, Ackery DM, Blake GM, Waller DG. Comparison of radionuclide estimation of glomerular filtration rate using technetium 99m diethylenetriaminepentaacetic acid and chromium 51 ethylenediaminetetraacetic acid. Eur J Nucl Med 1991;18:391-5.
25. 99mTc-DTPA renography using a dual head gamma camera. Nucl Med Commun 2004;25:1021-9.
26. Verhaeren EH, Dreessen MJ, Lemli JA. Influence of 1,8- dihydroxyanthraquinone and loperamide on the paracellular permeability across colonic mucosa. J Pharm Pharmacol 1981;33:526-8.
27. Panwar P, Iznaga-Escobar N, Mishra P, Srivastava V, Sharma RK, Chandra R, et al. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther 2005;4:854-60.
28. Frennby B, Sterner G. Contrast media as markers of GFR. Eur Radiol 2002;12:475-84.
29. Piepsz A. Radionuclide studies in paediatric nephro-urology. Eur J Radiol 2002;43:146-53.
30. Reiman RE, Benua RS, Gelbard AS, Allen JC, Vomero JJ, Laughlin JS. Imaging of brain tumors after administration of L-(N-13)glutamate: concise communication. J Nucl Med 1982;23:682-7.
31. Gelbard AS, Benua RS, Laughlin JS, Rosen G, Reiman RE, McDonald JM. Quantitative scanning of osteogenic sarcoma with nitrogen-13-labeled L-glutamate. J Nucl Med 1979;20:782-4.
32. Sordillo PP, Reiman RE, Gelbard AS, Benua RS, Magill GB, Laughlin JS. Scanning withL-(13 N) glutamate: assessment of the response to chemotherapy of a patient with embryonal rhabdomyosarcoma. Am J Clin Oncol 1982;5:285-9.
33. Jordan VC. Designer estrogens. Sci Am 1998;279:60-7.